Integrated development environment

Tektronix Introduces Open-Source Python-Native Driver Package for Test & Measurement Instrumentation

Retrieved on: 
Tuesday, November 14, 2023

BEAVERTON, Ore., Nov. 14, 2023 /PRNewswire/ -- Tektronix, Inc, a leading provider in test and measurement solutions, today announced the introduction of an open-source Python instrument driver package. Available free of charge, the package provides a native Python user experience for instrument automation. With integration into daily workflows and utilizing it with a preferred Integrated Development Environment (IDE), customers can now experience the power of auto-complete, precise type hinting, comprehensive built-in help, real-time syntax checking and enhanced debugging capabilities, resulting in unparalleled capabilities for seamless instrument automation. The open-source Python driver package is designed to work across a wide range of Tektronix and Keithley devices to facilitate ongoing development and updates, ensuring users in the test and measurement space have access to the latest features and improvements.

Key Points: 
  • The innovative package dramatically improves the test automation user experience, providing seamless instrument control for Tektronix and Keithley customers
    BEAVERTON, Ore., Nov. 14, 2023 /PRNewswire/ -- Tektronix, Inc , a leading provider in test and measurement solutions, today announced the introduction of an open-source Python instrument driver package .
  • The open-source Python driver package is designed to work across a wide range of Tektronix and Keithley devices to facilitate ongoing development and updates, ensuring users in the test and measurement space have access to the latest features and improvements.
  • The driver package, called tm_devices, is now available globally via the Python Package Index (PyPI) at pypi.org/project/tm-devices .)
  • For more details on the tm_devices open-source Python driver package, visit Tek.com .

Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform

Retrieved on: 
Monday, November 6, 2023

Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced Cabaletta will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership (TAP) program.

Key Points: 
  • Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced Cabaletta will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership (TAP) program.
  • Cellares’ innovative manufacturing technology transforms autologous and allogeneic cell therapy processes, covering nearly 90% of cell therapy modalities.
  • Through its TAP program, Cellares can facilitate the automation and tech transfer of manual processes onto the Cell Shuttle manufacturing platform in just six months.
  • With automation, standardization, and software-defined manufacturing (SDM), subsequent tech transfers become instant to any other Cell Shuttle in any IDMO Smart Factory worldwide.

Kim Launches Application Generator

Retrieved on: 
Wednesday, October 18, 2023

ATLANTA, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Kim ( www.kimdocument.com ), the no-code, SaaS, patent-protected document generation, assembly, and workflow automation platform, announces the launch of Application Generator.

Key Points: 
  • ATLANTA, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Kim ( www.kimdocument.com ), the no-code, SaaS, patent-protected document generation, assembly, and workflow automation platform, announces the launch of Application Generator.
  • Kim’s Application Generator enables individuals in organizations to generate entire web applications from their existing documents with no IT development or coding skills and no false positive errors.
  • Open Kim, select 'Create Application' and upload the tagged document.
  • Kim creates the entire application with no-code citizen development, including conditional document assembly and automatic generation of multiple documents off one document.

dbt Labs Announces Major Enhancements to dbt Cloud to Enable Collaboration at Scale

Retrieved on: 
Tuesday, October 17, 2023

SAN DIEGO, Oct. 17, 2023 /PRNewswire/ -- dbt Labs, the pioneer in analytics engineering, today announced several new product capabilities to its dbt Cloud platform at its annual customer conference, Coalesce 2023. New dbt Cloud capabilities enable customers to adopt dbt at scale and include dbt Explorer, Cloud CLI, new partner adapters, and the next generation of the dbt Semantic Layer. dbt Labs also announced the new dbt Mesh paradigm, which equips teams to collaborate across projects to support a data mesh architecture, enabled by the new capabilities. These announcements provide organizations with a centralized data transformation platform where everyone can contribute to data in a governed manner with increased velocity, quality, consistency, and coordination.

Key Points: 
  • New dbt Cloud capabilities enable customers to adopt dbt at scale and include dbt Explorer, Cloud CLI, new partner adapters, and the next generation of the dbt Semantic Layer.
  • "We first introduced dbt Cloud to help data analysts and engineers productionize dbt deployments," said Tristan Handy, CEO and founder of dbt Labs.
  • Additionally, dbt Labs is expanding the ecosystem of cloud data platforms that dbt Cloud inter-operates with, announcing upcoming adapters for Microsoft Azure Synapse and Microsoft Fabric.
  • The new dbt Semantic Layer is accessible to data platforms supported by dbt Cloud, namely BigQuery, Databricks, Redshift, and Snowflake.

Cellares Announces Expanded Agreement with Bristol Myers Squibb to Include Second CAR-T Program in Cellares’ Technology Adoption Partnership Program

Retrieved on: 
Wednesday, October 11, 2023

Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, announced that global biopharmaceutical company and cell therapy leader Bristol Myers Squibb (NYSE: BMY) will enter a second proof-of-concept tech transfer process for the manufacture of a CAR-T cell therapy, as part of the Cellares Technology Adoption Partnership (TAP) program.

Key Points: 
  • Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, announced that global biopharmaceutical company and cell therapy leader Bristol Myers Squibb (NYSE: BMY) will enter a second proof-of-concept tech transfer process for the manufacture of a CAR-T cell therapy, as part of the Cellares Technology Adoption Partnership (TAP) program.
  • As part of this expanded agreement, Cellares will optimize, automate, and tech-transfer the additional CAR-T cell therapy process onto its automated manufacturing platform, the Cell Shuttle.
  • Cellares’ TAP program is a fast and low-risk opportunity for cell therapy developers to adopt the company’s automated manufacturing technology for products in their pipeline.
  • Under the TAP program, manual processes can be automated and tech-transferred onto Cellares’ Cell Shuttle platform in only six months.

Unqork Creates First Integrated Development Environment (IDE) UDesigner Without Using Code, Introduces Integration Gateway to Accelerate Digital Transformation

Retrieved on: 
Wednesday, October 4, 2023

NEW YORK, Oct. 4, 2023 /PRNewswire/ -- Unqork, the leading codeless platform, today announced the next generation of the Unqork platform built entirely on codeless architecture and without using code, starting with its Integrated Development Environment (IDE), UDesigner, and Integration Gateway releases. UDesigner is the new way for cross-functional teams to deliver future-proof applications while reducing time-to-market. Integration Gateway will accelerate digital transformation by easily and securely integrating over 700+ third-party systems.

Key Points: 
  • Codeless IDE UDesigner and Integration Gateway enable more efficient cross-functional team collaboration, greatly expand third-party integration catalog
    NEW YORK, Oct. 4, 2023 /PRNewswire/ -- Unqork , the leading codeless platform, today announced the next generation of the Unqork platform built entirely on codeless architecture and without using code, starting with its Integrated Development Environment (IDE), UDesigner, and Integration Gateway releases.
  • Integration Gateway will accelerate digital transformation by easily and securely integrating over 700+ third-party systems.
  • To improve confidence and time-to-market, UDesigner brings together business and technical teams by allowing for tailored roles and two-way, real-time communication during development.
  • The next step in the evolution of the Unqork platform represents a substantial reinvestment in Unqork's codeless architecture standard and vision for code-free, enterprise-grade application development.

Digma Launches First-Ever Continuous Feedback Platform to Validate and Improve Developer and GenAI Code

Retrieved on: 
Tuesday, September 26, 2023

SANTA CLARA, Calif., Sept. 26, 2023 /PRNewswire-PRWeb/ -- Digma has launched the world's first Continuous Feedback platform to enable developers to continuously analyze their code at runtime to identify issues and regressions, preventing bad code from making it to production, including GenAI-generated code.

Key Points: 
  • Digma acts as a guardrail by providing continuous real-time analysis of the code, presented to the developer as they code and in the IDE before the code gets pushed to production."
  • Nir Shafrir, Digma CEO
    The new platform looks for regressions, anomalies, code smells, and other patterns to flag to developers to improve their code.
  • Digma acts as a guardrail by providing continuous real-time analysis of the code, presented to the developer as they code and in the IDE before the code gets pushed to production."
  • Continuous Feedback reduces the risk surrounding checking-in code changes to complex systems or when using GenAI code."

Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform

Retrieved on: 
Monday, September 11, 2023

Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Lyell Immunopharma (NASDAQ: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced Lyell will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership (TAP) program.

Key Points: 
  • Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellares , the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, and Lyell Immunopharma (NASDAQ: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced Lyell will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle™, through Cellares’ Technology Adoption Partnership (TAP) program.
  • As part of the collaboration, the companies have agreed on a proof-of-concept technology transfer process for the manufacture of Lyell’s LYL797 CAR T-cell therapy, using the Cell Shuttle.
  • Cellares' innovative manufacturing technology transforms autologous and allogeneic cell therapy processes, covering nearly 90% of cell therapy modalities.
  • Through their TAP program, Cellares can facilitate the automation and tech transfer of manual processes onto the Cell Shuttle manufacturing platform in just six months.

Coder 2.0 Lets Developers Create, Access and Collaborate from Anywhere

Retrieved on: 
Wednesday, September 13, 2023

Coder simplifies cloud-based development so that developers can focus on their work," said Elliot Graebert, Skydio's Director of Engineering, Infrastructure.

Key Points: 
  • Coder simplifies cloud-based development so that developers can focus on their work," said Elliot Graebert, Skydio's Director of Engineering, Infrastructure.
  • The benefits are so compelling that a third of Skydio's developers are using Coder on a daily basis."
  • New features in Coder 2.0 include:
    Envbuilder for Dev Containers, an open source project by Coder based on the Microsoft Dev Containers specification.
  • Today, Coder and its founders remain driven by the goal of keeping developers in flow by providing limitless computational power and storage, allowing developers to build applications and collaborate quickly and easily, in real time.

Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform

Retrieved on: 
Monday, August 28, 2023

Cellares' TAP program is a fast and low-risk opportunity for cell therapy developers to adopt the company's automated manufacturing technology for products in their pipeline.

Key Points: 
  • Cellares' TAP program is a fast and low-risk opportunity for cell therapy developers to adopt the company's automated manufacturing technology for products in their pipeline.
  • Bristol Myers Squibb is leveraging this program to evaluate the automated manufacturing process and produce comparability data confirming the Cell Shuttle as a viable, cost-efficient, and scalable manufacturing solution for cell therapies.
  • Cellares' flexible manufacturing technology supports both autologous and allogeneic cell therapy processes and approximately 90% of cell therapy modalities.
  • Manual processes can be automated and tech-transferred onto Cellares' automated Cell Shuttle platform in only six months via the company's Technology Adoption Partnership (TAP) program.